Oncolytics to Present REO 033 Colorectal Cancer Trial Abstract at ESMO
Oncolytics says its study launched earlier this year is expected to assess a prior efficacy signal in second-line KRAS-mutant MSS colorectal cancer: 17 months of progression-free survival versus six months for historical standard of care.
Story updates
01:43:19 PM UTC
SquawkNews
Oncolytics Biotech will present a REO 033 trial—in—progress abstract and e-poster at ESMO 2026 highlighting pelareorep in second-line RAS—mutant, MSS metastatic colorectal cancer.Key Highlights:Original SEC Filing: ONCOLYTICS BIOTECH INC [ ONCY ] - 8-K - Oct. 20, 2026This is an AI-powered summary…